Brief: Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals
Aug 16 (Reuters) - Eyenovia Inc EYEN.O :
* EYENOVIA ACQUIRES U.S. COMMERCIAL RIGHTS TO APP13007
(CLOBETASOL
PROPIONATE OPHTHALMIC NANOSUSPENSION, 0.05%) FROM FORMOSA
PHARMACEUTICALS
* EYENOVIA INC - PLANS TO EVALUATE NOVEL CLOBETASOL
FORMULATIONS
IN ITS PROPRIETARY OPTEJET DISPENSING PLATFORM AS A POTENTIAL
TREATMENT FOR DRY EYE
Source text for Eikon: ID:nGNX2kmW89
Further company coverage: EYEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyperion DeFi
See all newsHyperion DeFi Inc reports results for the quarter ended September 30 - Earnings Summary
Hyperion DeFi posts third straight record quarterly profit
Hyperion DeFi Inc expected to post earnings of $1.81 a share - Earnings Preview
Brief: Hyperion Defi Raises Guidance And Announces $20M Share Repurchase Program
Hyperion DeFi Inc reports results for the quarter ended June 30 - Earnings Summary